Pathstone Holdings
STRO icon

Pathstone Holdings’s Sutro Biopharma STRO Stock Holding History

Pathstone Holdings’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,360
Closed -$81.6K – 2397
2024
Q3 		$81.6K Buy
2,360
+14
+0.6% +$549 ﹤0.01% 2257
2024
Q2 		$68.7K Buy
2,346
+65
+3% +$2.57K ﹤0.01% 2248
2024
Q1 		$129K Buy
+2,281
New +$101K ﹤0.01% 2200

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Pathstone Holdings's STRO Position: Q4 2024 in Review

Pathstone Holdings sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 2,360 shares — an estimated $81.6K sold.

Pathstone Holdings first reported a position in STRO in Q1 2024 and held it in 3 quarters. The position peaked at $129K in Q1 2024. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • Pathstone Holdings reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • Pathstone Holdings sold 2,360 Sutro Biopharma shares in Q4 2024, an estimated $81.6K.
  • Pathstone Holdings first reported a position in Sutro Biopharma in Q1 2024 and held it in 3 quarters.
  • Pathstone Holdings's Sutro Biopharma position peaked at $129K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on Pathstone Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.